RXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RXRX is not a good buy right now for an impatient buyer. The chart is still in a clear downtrend (bearish moving-average stack and worsening MACD), price is sitting on near-term support (4.255) with risk of a breakdown toward ~4.01, and there are no Intellectia entry signals today. While options positioning is bullish-leaning and RSI is near oversold (bounce potential), the prevailing trend and weak recent fundamentals make the risk/reward unattractive for an immediate entry.
Trend/structure: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend. Momentum: MACD histogram is negative (-0.0431) and expanding bearishly, suggesting downside momentum is still building rather than stabilizing. RSI: RSI(6) at 31.376 is near oversold, which can allow short-term bounces, but it is not a reversal signal by itself while MACD/MA remain bearish. Levels: Current price ~4.255 is right at S1 (4.255). A clean loss of this level increases odds of a move toward S2 (4.005). Upside resistance to reclaim: Pivot 4.66, then R1 5.065. Pattern-based forecast: Similar-pattern stats imply ~50% chance of -1.8% next day, +1.1% next week, and -2.95% next month—skewing negative on the time horizon that matters for an impatient entry.
Intellectia Proprietary Trading Signals
Options market skew: Call-heavy put/call ratios suggest traders are positioned for upside or a rebound move.
Technical deterioration: Downtrend remains intact with bearish MA stack and worsening MACD—no confirmation of a durable bottom.
Business model risk (news flow): Repeated emphasis that the company has no approved products yet and is still mid-stage on key candidates; market confidence has been weakened after a large 2025 drawdown.
Competitive pressure: News highlights intense competition from larger pharma (e.g., Eli Lilly), which can compress long-term probability-weighted upside.
Event risk asymmetry: Clinical updates can be volatile; without a confirmed uptrend, negative or merely “incremental” data can pressure shares further.
Latest quarter: 2025/Q3. Revenue: $5.175M, down ~80.16% YoY (sharp contraction). Profitability: Net income improved YoY (loss narrowed) to -$162.253M (up 69.29% YoY), and EPS improved to -0.36 (up 5.88% YoY), but the company remains deeply loss-making. Margins: Gross margin fell to -183.81 (meaningfully worse YoY), indicating poor near-term operating leverage/quality of revenue. Takeaway: Financials do not yet show a clean improving growth trend; the story remains primarily catalyst-driven (pipeline/data) rather than fundamentals-driven.
Recent trend: Bullish revision from JPMorgan (2025-12-17) upgraded RXRX to Overweight from Neutral and raised price target to $11 (from $10), citing stronger-than-expected REC-4881 potential and encouraging early signs for REC-617. Wall Street pros: Large upside optionality if REC-4881/REC-617/other programs succeed; platform narrative (AI drug discovery) can attract partnership and pipeline re-rating; upcoming readouts can be catalysts. Wall Street cons: Execution and clinical risk remain high with no approved products; competitive landscape is tough; recent stock underperformance has weakened confidence. Positioning/flows: Hedge funds and insiders are reported as Neutral (no significant recent trend). Congress trading: no recent data available. Politician/influential-figure trading: none provided in the dataset.
